赛诺医疗(688108) - 2025 Q2 - 季度业绩预告

Sino Medical 2025 Semi-Annual Performance Forecast Performance Forecast and Year-on-Year Comparison The company projects significant growth in its 2025 semi-annual performance, with substantial increases in revenue and net profit, including a turnaround in non-recurring adjusted net profit Key Financial Performance Comparison | Financial Metric | 2025 H1 (Forecast) (RMB Million) | 2024 H1 (Prior Period) (RMB Million) | YoY Change | | :--- | :--- | :--- | :--- | | Operating Revenue | 240.48 | 213.69 | +12.53% | | Net Profit Attributable to Shareholders | 13.84 | 3.49 | +296.54% | | Net Profit Attributable to Shareholders (Excluding Non-Recurring Items) | 7.98 | -12.59 | +163.35% (Turnaround) | - The financial data in this performance forecast has not been audited by a certified public accountant[4] Analysis of Performance Growth Drivers The core drivers for this period's performance growth are increased sales of core products and effective cost control, despite negative impacts from reduced investment income and asset impairment losses - Significant sales growth in core products, including two coronary stent products and coronary balloon products, due to their inclusion in national centralized procurement[5] - Stable development in emerging businesses, with neuro-interventional business maintaining steady growth[5] - Effective cost control, with year-on-year decreases in selling and R&D expenses, though administrative expenses increased[5] - Negative influencing factors include a significant year-on-year decrease in investment income and asset impairment losses, partially dragging down profit growth[5] Important Statements and Risk Warnings The company confirms no material uncertainties affecting the accuracy of this performance forecast as of the announcement date, while reminding investors that the disclosed data is preliminary and subject to the final 2025 semi-annual report - The company confirms no material uncertainties currently affect the accuracy of this performance forecast[6] - The company emphasizes that this forecast data is preliminary, and final figures will be based on the officially disclosed 2025 semi-annual report[7]